Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
Parma, Italy, and Cleveland, Ohio (ots/PRNewswire) - - New investment will progress treatment of pulmonary arterial hypertension (PAH), a rare condition which causes high blood pressure in the blood vessels that supply the lungs and can lead to heart failure. - Current approved medications mainly address the ...
mehr